AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05307250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolstered Standard of Care (BSOC)
Description: All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
Study NCT05924672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Given IV
Study NCT05924672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA Positron Emission Tomography (PET) Scan
Description: Undergo PSMA PET/CT
Study NCT05924672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M Medronate
Description: Undergo MDP
Study NCT04808427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TULSA-PRO
Description: Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
Study NCT05887674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Low inflammatory-index diet
Study NCT05887674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Guided muscle strength training and stretching exercises
Study NCT05887674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training will be implemented in person
Study NCT06650553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
Description: This clinical trial is divided into three stages: the screening phase, the treatment phase, and the follow-up phase. During the screening phase, patient enrollment must be completed, and baseline conditions must be recorded. In the treatment phase, the transplantation treatment process for patients in the HLA-matched HSCT group and the umbilical cord blood-supported haplo-HSCT group must be completed, and treatment conditions must be recorded. In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
Study NCT05439291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Epilation Regimen
Description: Epilation using laser device
Study NCT05439291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of pilonidal pit with trephine
Study NCT05925309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem
Description: Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
Study NCT05925309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem
Description: Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
Study NCT05925309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
Description: Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
Study NCT05146700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restrictive oxygen
Description: Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
Study NCT05146700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal oxygen
Description: 15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
Study NCT04233788 — intervention group
Intervention type: DEVICE
Intervention: MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)
Description: The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
Study NCT05138861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Description: A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
Study NCT06129448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
Study NCT05001893 — intervention group
Intervention type: DEVICE
Intervention: S53P4 bioactive glass putty
Description: Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
Study NCT04861077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FMISO-PET with contrast-enhanced MRI
Description: Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
Study NCT06469736 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard of Care Ureterorenoscopy
Description: The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
Study NCT06469736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Ureterorenoscopy with MediNiK
Description: The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
Study NCT06420323 — intervention group
Intervention type: DEVICE
Intervention: Treatment with NovoX® Cup
Description: NovoX® Cup treatment
Study NCT06420323 — intervention group
Intervention type: DEVICE
Intervention: Treatment with Omnistrip®
Description: Omnistrip® treatment
Study NCT06463886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-AD
Description: This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
Study NCT06463886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual (E-TAU)
Description: Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
Study NCT06348823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: volume survey
Description: All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
Study NCT06652009 — intervention group
Intervention type: OTHER
Intervention: Radical nephroureterectomy
Description: Radical nephroureterectomy
Study NCT06652009 — intervention group
Intervention type: RADIATION
Intervention: Radical radiotherapy
Description: Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
Study NCT06653790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulations
Description: The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
Study NCT05634629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Lamellar Recession
Description: ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
Study NCT05634629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilamellar Tarsal Rotation
Description: the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
Study NCT06024746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Oral finerenone.
Study NCT06024746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Oral empagliflozin.
Study NCT06398704 — intervention group
Intervention type: OTHER
Intervention: Standart of care
Description: No additional intervention was made. An evaluation was made.
Study NCT04631185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single pre-operative dose of intravenous antibiotics with intraoperative redosing
Description: Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
Study NCT04631185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single pre-operative dose of intravenous antibiotics with intraoperative redosing
Description: Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
Study NCT05695001 — intervention group
Intervention type: DEVICE
Intervention: Efferon CT
Description: Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
Study NCT05584501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Navigator
Description: The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
Study NCT05584501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting
Description: Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
Study NCT05584501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting
Description: Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
Study NCT04631185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One week of post-operative antibiotics
Description: The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
Study NCT05897216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study NCT05897216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150, D029
Description: QD, PO
Study NCT05638607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified occupational therapy
Description: The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
Study NCT05638607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified occupational therapy
Description: The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
Study NCT06521138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing group
Description: The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
Study NCT06521138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group will receive routine care at the center.
Study NCT06653088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Education program
Description: A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility.
Study NCT06487832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP1-RA
Description: Subcutaneous administration of semaglutide
Study NCT06487832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous placebo
Description: Subcutaneous administration of NaCl
Study NCT05322317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADVANCE-PC training via ECHO
Description: To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
Study NCT06377735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BAI-BACE
Description: Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
Study NCT05976334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Subasumstat
Description: \[14C\] Subasumstat IV infusion.
Study NCT05976334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subasumstat
Description: Subasumstat IV infusion.
Study NCT05280574 — intervention group
Intervention type: DEVICE
Intervention: GE Portrait Monitor
Description: All patients will be monitored
Study NCT05280574 — intervention group
Intervention type: DEVICE
Intervention: GE Portrait Monitoring with intervened by clinician
Description: Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
Study NCT05280574 — intervention group
Intervention type: DEVICE
Intervention: GE Portrait Monitoring randomized to blinded or unblinded
Description: Without intervention